secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116777
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast
----------------------------------------------------------------------------

- Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.
- Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).
- Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.
- 2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.
- Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/0001104659-24-116777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/tm2427439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer